



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
ASSISTANT SECRETARY AND COMMISSIONER
OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

AUG 27 1998

W. Scott McNees
Cytogen Corporation
600 College Road East
Princeton, NJ 08540

Re: Patent Term Extension
Application for
U.S. Patent No. 5,162,504

Dear Mr. McNees:

A certificate under 35 U.S.C. § 156 is enclosed extending the term of U.S. Patent No. 5,162,504 for a period of 352 days.

Telephone inquiries regarding this communication should be directed to the undersigned at (703)306-3159.

Karin Tyson
Legal Advisor
Special Program Law Office
Office of the Deputy Assistant Commissioner
for Patent Policy and Projects

cc: Ronald L. Wilson, Director
Health Assessment Policy Staff
Office of Health Affairs (HFY-20)
Food and Drug Administration
5600 Fishers Lane, Room 15-22
Rockville, MD 20857

RE: ProstaScint™ (capromab pendetide)
FDA Docket No.: 97E-0107

kt

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE EXTENDING PATENT TERM UNDER 35 U.S.C. § 156

PATENT NO. : 5,162,504
ISSUED : November 10, 1992
INVENTOR(S) : Julius S. Horoszewicz
PATENT OWNER : Cytogen Corporation

This is to certify that there has been presented to the

COMMISSIONER OF PATENTS AND TRADEMARKS

an application under 35 U.S.C. § 156 for an extension of the patent term. Since it appears that the requirements of the law have been met, this certificate extends the term of the patent for the period of

352 days

from November 10, 2009, the original expiration date of the patent, subject to the provisions of 35 U.S.C. § 41(b), with all rights pertaining thereto as provided by 35 U.S.C. § 156(b).



I have caused the seal of the Patent and Trademark Office to be affixed this 27th day of August 1998.


Bruce A. Lehman

Assistant Secretary of Commerce and
Commissioner of Patents and Trademarks